secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001493152-24-036855
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA
------------------------------------------------------------------------

- Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.
- Underwriters granted 45-day option for additional 232,500 shares at same price.
- Proceeds to fund Phase 1 lung cancer and Phase 2 prostate cancer trials for lead candidate ENV 105.
- Issued two warrants to underwriters for 54,250 shares each at $4.80 exercise price, exercisable from Mar 2025 to Sep 2029.
- Common stock began trading on NYSE American on Sept 16, 2024 under symbol KAPA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224036855/0001493152-24-036855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315224036855/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-036855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer